Spyre Therapeutics Inc (NASDAQ: SYRE) on Friday, soared 3.16% from the previous trading day, before settling in for the closing price of $23.13. Within the past 52 weeks, SYRE’s price has moved between $15.41 and $47.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -49.91%. The company achieved an average annual earnings per share of 91.27%. With a float of $50.01 million, this company’s outstanding shares have now reached $51.40 million.
Let’s determine the extent of company efficiency that accounts for 30 employees. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Spyre Therapeutics Inc is 14.81%, while institutional ownership is 81.99%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.27% per share during the next fiscal year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Spyre Therapeutics Inc (SYRE) is currently performing well based on its current performance indicators. A quick ratio of 7.32 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.99 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Looking closely at Spyre Therapeutics Inc (NASDAQ: SYRE), its last 5-days average volume was 0.7 million, which is a jump from its year-to-date volume of 0.53 million. As of the previous 9 days, the stock’s Stochastic %D was 16.78%. Additionally, its Average True Range was 1.88.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 7.29%, which indicates a significant decrease from 19.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.60% in the past 14 days, which was higher than the 61.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.27, while its 200-day Moving Average is $31.23. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $24.95. Second resistance stands at $26.05. The third major resistance level sits at $27.21. If the price goes on to break the first support level at $22.69, it is likely to go to the next support level at $21.53. Now, if the price goes above the second support level, the third support stands at $20.43.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
Market capitalization of the company is 1.44 billion based on 51,431K outstanding shares. Right now, sales total 890 K and income totals -338,790 K. The company made 0 K in profit during its latest quarter, and -69,030 K in sales during its previous quarter.
